Schering AG possesses an advanced collection of identified SEGRAs, which could be used to treat a number of diseases. Schering and AstraZeneca will undertake a joint R&D program up to the end of phase I clinical trials aimed at identifying novel SEGRAs.
Under the terms of the three-year agreement, AstraZeneca will have an exclusive, worldwide license to develop and market compounds for rheumatoid and respiratory diseases, while Schering will have an exclusive, worldwide license to all other indications. Schering will receive upfront fees, with both parties having the potential to benefit from milestone payments and royalties.
“The collaboration with AstraZeneca is an excellent opportunity for us to fully explore the potential of SEGRAs and capitalize on the full value of these compounds”, said Dr Khusru Asadullah, head of inflammation research for Schering AG.